Peptide benefits guides

Small-molecule NNMT inhibitor discussed in early-stage experimental metabolic and weight-related research.

An experimental soluble activin receptor (ACVR2B) fusion protein studied for inhibiting myostatin and activin to promote muscle mass.

Experimental targeted peptide studied in preclinical models for reducing fat tissue by acting on its blood supply.

A copper-binding tripeptide studied mainly in cosmetic/skin and hair contexts for signaling effects on tissue and follicles.

An AMPK-activating compound studied as an exercise mimetic in metabolic and endurance research.

A prostaglandin E1 analog (a vasodilator) used medically for erectile dysfunction and certain circulatory conditions.

Synthetic peptide derived from the C-terminal portion of human growth hormone, discussed for potential effects on fat metabolism.

Peptide derived from erythropoietin (cibinetide) studied in small randomised trials for tissue-protective and anti-inflammatory effects.

A single-chain peptide derived from the hormone relaxin (H2), studied preclinically for anti-fibrotic effects in heart, lung, and kidney tissue.

Sterile water containing a bacteriostatic preservative, supplied as a diluent for reconstituting compatible medications rather than as an active therapeutic.

A potent neurotoxin that blocks acetylcholine release at nerve terminals; used medically and cosmetically to relax targeted muscles.

Synthetic peptide fragment often discussed for tissue healing and GI-related effects.

A vendor blend of BPC-157, GHK-Cu, and KPV combining repair, skin-signaling, and anti-inflammatory components; no dedicated trials.

Combination catalog entry bundling BPC-157, GHK-Cu, and TB-500 around tissue-repair and cosmetic themes; no dedicated trials.

Combination catalog entry bundling four peptides discussed for healing, cosmetic, and anti-inflammatory themes; no dedicated trials.

Combination catalog entry pairing BPC-157 with TB-500, two peptides often discussed for tissue repair; no dedicated trials.

A short peptide bioregulator studied in Russian research for respiratory/bronchial tissue; limited independent evidence.

Long-acting amylin analog studied for chronic weight management, usually alongside a GLP-1 receptor agonist.

Fixed-dose combination of an amylin analog and a GLP-1 receptor agonist studied for obesity and metabolic disease.

A short peptide bioregulator studied for cardiovascular/heart tissue; mostly older Russian research.

A short peptide bioregulator studied in the context of cartilage and joint tissue; limited evidence.

Injectable mixture of low-molecular-weight peptides and amino acids derived from porcine brain, used in some regions for neurologic indications.

A short peptide bioregulator studied for respiratory epithelium and lung tissue; limited independent data.

Vendor blend pairing a GHRH analog with a selective ghrelin-receptor agonist; the combination itself has never been tested in a published human trial.

Long-acting growth hormone–releasing hormone analog designed to extend GH and IGF-1 stimulation, discussed in experimental and wellness contexts.

Shorter-acting GHRH analog (modified GRF 1-29) discussed for stimulating GH release without a long-acting DAC modification.

A short peptide bioregulator studied for brain/cortex neuroprotection in Russian research; limited evidence.

A short peptide bioregulator studied for immune-system regulation; mostly older Russian research.

Potent opioid-like peptide originally isolated from amphibian skin, occasionally discussed in experimental analgesia and performance contexts.

An angiotensin IV-derived peptide studied preclinically for synaptogenesis and cognition via HGF/c-Met signaling.

Small peptide historically studied for effects on sleep and stress, now mostly of experimental and niche interest.

A long-acting GLP-1 receptor agonist (marketed as Trulicity) used for type 2 diabetes; note vendor 'research' vials are not the approved product.

Synthetic tetrapeptide discussed in aging and longevity circles on the basis of limited, region-specific research.

A hormone that stimulates red blood cell production; used medically for anemia and notoriously misused (and WADA-banned) in endurance sport.

A follistatin variant studied for binding and inhibiting myostatin, a negative regulator of muscle growth.

Experimental peptide discussed in senolytic and cellular-aging research, studied almost entirely in preclinical settings.

Growth differentiation factor 8, the natural myostatin protein that limits muscle growth; studied as a research reagent and drug target.

Naturally occurring copper-binding tripeptide with a topical cosmetic evidence base for skin appearance and essentially no human safety data as an injectable.

Growth hormone–releasing peptide (pralmorelin) from an earlier generation of GH secretagogues, used as a diagnostic agent in some regions.

Growth hormone–releasing peptide from the same family as GHRP-2, historically discussed for GH release and appetite stimulation.

Endogenous tripeptide antioxidant given orally or parenterally in wellness and hepatology contexts, with mixed evidence.

A gonadotropin-releasing hormone (GnRH) analog studied for stimulating LH and FSH release in reproductive and hormonal contexts.

Hormone with LH-like activity used in regulated reproductive and endocrine medicine, and discussed more broadly in wellness and performance contexts.

Potent growth hormone secretagogue from an earlier generation of GH-axis agents, now largely of historical and experimental interest.

Recombinant human growth hormone with the same 191–amino acid sequence as endogenous GH, used in regulated settings for growth hormone–related conditions.

A C-terminal fragment of growth hormone studied for lipolytic (fat-loss) effects without growth hormone's growth signaling.

Menotropins: a gonadotropin preparation with FSH- and LH-like activity used in regulated fertility and endocrine settings.

A mitochondrial-derived peptide studied for cytoprotective and metabolic signaling in aging research.

A naturally occurring glycosaminoglycan used in skin, joint, and cosmetic contexts for hydration and tissue support.

Long-acting insulin-like growth factor-1 analog discussed in experimental growth-factor contexts, with no clinical trial literature.

Truncated insulin-like growth factor-1 analog discussed for localized growth-factor signaling in experimental settings.

The essential peptide hormone regulating blood glucose; a prescription medication with serious hypoglycemia risk if misused.

Selective growth hormone secretagogue and ghrelin-receptor (GHS-R1a) agonist whose corporate clinical program was discontinued.

A vendor blend pairing the GHRH analog tesamorelin with the selective secretagogue ipamorelin for complementary growth hormone signaling; no dedicated trials.

Peptide fragment of the kisspeptin family studied for its role in reproductive hormone signaling in endocrine and fertility research.

Tripeptide fragment often discussed for anti-inflammatory and gut-related effects.

An amino acid derivative involved in transporting fatty acids into mitochondria for energy; used in metabolic and fat-metabolism contexts.

A cosmetic fat-dissolving (lipolysis) injectable — not a peptide — marketed with riboflavin, bromelain, and lecithin; not FDA/MHRA/CE approved.

Injectable mixture of lipotropic agents and B vitamins marketed in wellness settings for energy and weight-related goals, with limited evidence.

Injectable mixture of lipotropic agents without added B vitamins, marketed for metabolic or weight-related support.

A daily GLP-1 receptor agonist (marketed as Victoza/Saxenda) for diabetes and weight; vendor 'research' vials are not the approved product.

A short peptide bioregulator studied for liver tissue; mostly older Russian research, limited independent evidence.

Human cathelicidin-derived peptide discussed for roles in innate immunity and tissue defense, largely in experimental contexts.

A cosmetic 'matrikine' peptide (palmitoyl pentapeptide) used topically in anti-aging skincare to signal collagen support.

Dual GLP-1 and glucagon receptor agonist studied for obesity and type 2 diabetes; approved in China and investigational elsewhere.

The pineal hormone that regulates the sleep-wake cycle; widely used as a sleep aid and studied for circadian and antioxidant effects.

Mechano growth factor, an IGF-1 splice variant (IGF-1Ec) produced by mechanically stressed muscle and studied for muscle repair.

Orally active ghrelin-receptor agonist and growth hormone secretagogue studied for raising growth hormone and IGF-1.

Mitochondrial-derived peptide studied for roles in metabolic regulation, insulin sensitivity, and cellular stress responses.

Synthetic alpha-MSH analog (afamelanotide) approved as Scenesse for erythropoietic protoporphyria and discussed more broadly for skin pigmentation.

Synthetic melanocortin receptor agonist discussed in relation to tanning and sexual function, primarily in experimental and non-regulated contexts.

Nicotinamide adenine dinucleotide, a central cellular cofactor discussed in metabolic, aging, and mitochondrial health research.

A synthetic cosmetic peptide (derived from the antimicrobial peptide granulysin) used topically in skincare for its antibacterial and skin-clarifying properties.

A wake-promoting hypothalamic neuropeptide (hypocretin-1) that activates both orexin receptors (OX1R and OX2R); studied for arousal, appetite, and narcolepsy.

A wake-promoting hypothalamic neuropeptide (hypocretin-2) that preferentially activates the OX2R receptor; less stable than orexin A and less studied.

Endogenous peptide hormone involved in uterine contraction, lactation, and social behavior, with approved obstetric uses.

A peptide studied preclinically for neurogenesis and cognitive effects (distinct from the p21 cell-cycle protein of the same name).

A short peptide bioregulator studied for pancreatic tissue; mostly older Russian research.

A synthetic analog of spadin studied preclinically as a fast-acting antidepressant candidate via TREK-1 potassium-channel blockade.

Pegylated mechano growth factor analog discussed in experimental muscle and recovery contexts.

Short peptide complex marketed in Eastern European contexts as a neuroprotective peptide, with limited and region-specific evidence.

An experimental peptide studied preclinically for selectively disrupting cancer-cell membranes via an HDM-2 interaction.

A short peptide bioregulator studied for prostate tissue; mostly older Russian research, limited evidence.

Melanocortin receptor agonist approved as Vyleesi for hypoactive sexual desire disorder in premenopausal women.

Investigational triple agonist targeting GIP, GLP-1, and glucagon receptors.

Synthetic peptide derived from tuftsin, discussed for anxiolytic and nootropic effects in experimental and regional clinical literature.

GLP-1 receptor agonist commonly discussed for glycemic control and weight management.

Synthetic heptapeptide discussed for neuroprotective and nootropic effects, studied mainly in Eastern European literature.

A vendor blend of the nootropic Semax and the anxiolytic Selank, combining cognitive and anti-anxiety research peptides; no dedicated trials.

Synthetic growth hormone–releasing hormone analog, formerly marketed as Geref for diagnostic and paediatric growth use and now discussed in wellness settings.

Experimental small molecule discussed in preclinical metabolic and mitochondrial research, with no human data.

Cosmetic peptide (acetyl octapeptide-3) used in topical formulations and discussed for softening the appearance of facial lines.

Mitochondria-targeted tetrapeptide (elamipretide) with an FDA accelerated approval in Barth syndrome and a clearly negative phase 3 trial elsewhere.

Investigational dual GLP-1 and glucagon receptor agonist studied for obesity and metabolic disease.

Product name covering the actin-binding fragment of thymosin beta-4 — and, in some vials, the full-length protein — discussed for tissue repair.

A recombinant fragment of parathyroid hormone (marketed as Forteo) used medically to build bone in severe osteoporosis.

Synthetic growth hormone–releasing hormone analog approved in some regions for HIV-associated lipodystrophy and studied more broadly in metabolic research.

A short peptide bioregulator studied for testicular/reproductive tissue; mostly older Russian research.

Thymic-derived peptide mixture historically used in some regions for immune modulation, now primarily of historical and experimental interest.

Peptide derived from thymic proteins, discussed for immune-modulating effects and studied in selected infectious and oncologic contexts.

Dual GIP/GLP-1 receptor agonist frequently discussed for type 2 diabetes and obesity.

A gonadotropin-releasing hormone (GnRH) agonist used medically for hormone-sensitive conditions; continuous use down-regulates the reproductive axis.

A short (Lys-Glu) peptide bioregulator studied for immune modulation and aging; mostly older Russian research.

Endogenous neuropeptide involved in smooth muscle relaxation, vasodilation, and secretion; its synthetic form aviptadil has been trialled in serious illness.

Essential water-soluble vitamin involved in hematologic and neurologic function, given by injection when deficiency or absorption problems are present.